Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 15 January, 2019

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 1864N
GlaxoSmithKline PLC
15 January 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E N Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

1535.597

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

42.320

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S P Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

1050.550

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the

transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

0.012

 

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.4400

75.536

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

309.578

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.4400

18.799

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.4400

424.074

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

1945.478

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

 363.181

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

357.061

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

210.297

 

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs K Thomson

b)

Position/status

PCA of Mr P C Thomson (President, Global Affairs)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.2875

127.445

  

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHDELFFKFFFBBX

a d v e r t i s e m e n t